Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med

Kyle Blankenship

Locked in a heated battle for I/O supremacy, Merck and Bristol have readily engaged in proxy battles for new indications, tag-teaming their blockbusters with other …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med

Kyle Blankenship

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

An­oth­er Keytru­da com­bo tops stan­dard of care in ad­vanced kid­ney can­cer, pos­ing new test for Bris­tol's I/O med

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med